AssetMark’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
Other funds holding ACAD
AssetMark's ACAD Position: Q3 2026 in Review
AssetMark increased its Acadia Pharmaceuticals (ACAD) stake by 7.2% in Q3 2026, buying an estimated $671 and bringing the position to 370 shares worth $7.46K. The position accounts for ﹤0.01% of the portfolio, ranked #2620.
AssetMark first reported a position in ACAD in Q4 2015 and has held it in 9 quarters since. The position peaked at $8.73K in Q2 2026. 268 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.
- AssetMark held 370 shares of Acadia Pharmaceuticals worth $7.46K as of Q3 2026.
- AssetMark bought 25 Acadia Pharmaceuticals shares in Q3 2026, an estimated $671.
- Acadia Pharmaceuticals made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #2620 holding.
- AssetMark first reported a position in Acadia Pharmaceuticals in Q4 2015 and has held it in 9 quarters since.
- AssetMark's Acadia Pharmaceuticals position peaked at $8.73K in Q2 2026.
- 268 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.